Try
Amphastar Pharmaceuticals Inc. Common Stock
AMPHUnited States
5 filed reports · 342 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 1,189 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 968 | Dec 2025 |
Financial data
342 concepts · 2,157 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial323 concepts · 2,010 facts · Dec 2023 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Ending balance13 · Dec 2023 to Jun 2026
- Issuance of common stock in connection with the Company's equity plans13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent13 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of revenue (US GAAP)12 · Dec 2023 to Jun 2026
- Defined contribution plan cost recognized12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Incremental common shares attributable to contingently issuable shares12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Inventory write down12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax12 · Dec 2023 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
Segment16 concepts · 95 facts · Dec 2023 to Mar 2026
- Revenue27 · Dec 2023 to Mar 2026
- Advertising expense5 · Dec 2023 to Mar 2026
- Allocated share based compensation expense5 · Dec 2023 to Mar 2026
- Clinical trials expense5 · Dec 2023 to Mar 2026
- Consulting and outside services expense5 · Dec 2023 to Mar 2026
- Depreciation depletion and amortization5 · Dec 2023 to Mar 2026
- Income tax expense benefit5 · Dec 2023 to Mar 2026
- Interest expense nonoperating5 · Dec 2023 to Mar 2026
- Investment income interest5 · Dec 2023 to Mar 2026
- Labor and related expense5 · Dec 2023 to Mar 2026
- Marketing and advertising expense5 · Dec 2023 to Mar 2026
- Materials and supplies5 · Dec 2023 to Mar 2026
- Net income loss5 · Dec 2023 to Mar 2026
- Segment reporting other item amount5 · Dec 2023 to Mar 2026
- Income loss from equity method investments2 · Dec 2023 to Dec 2024
- Number of reportable segments1 · Mar 2026
Geography1 concepts · 36 facts · Dec 2023 to Jun 2026
- Revenue36 · Dec 2023 to Jun 2026
Product2 concepts · 16 facts · Dec 2023 to Dec 2025
- Revenue13 · Dec 2023 to Dec 2025
- Selling and marketing expense (US GAAP)3 · Dec 2023 to Dec 2025
Segments
147 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 68 facts
- Pharmaceutical Products68 · Dec 2023 to Mar 2026
Statement geographical3 members · 36 facts
- CN12 · Dec 2023 to Jun 2026
- FR12 · Dec 2023 to Jun 2026
- US12 · Dec 2023 to Jun 2026
Subsegments8 members · 27 facts
- Primatenemist8 · Dec 2023 to Mar 2026
- Epinephrine3 · Dec 2023 to Dec 2025
- Glucagon3 · Dec 2023 to Dec 2025
- Lidocaine3 · Dec 2023 to Dec 2025
- Other Products3 · Dec 2023 to Dec 2025
- Total Net Revenues By Product3 · Dec 2023 to Dec 2025
- Baqsimi2 · Dec 2024 to Dec 2025
- Other Revenues2 · Dec 2023 to Dec 2024
Product or service3 members · 16 facts
- Product9 · Dec 2023 to Dec 2025
- Product And Service Other4 · Dec 2023 to Dec 2024
- Shipping And Handling3 · Dec 2023 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
- FY2026 Q1May 8, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Nov 8, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.